Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Standard BioTools ( (LAB) ) has shared an update.
On January 30, 2026, Standard BioTools completed the sale of its aptamer-based and functional proteomics business, including SomaLogic and Sengenics entities and the SomaScan, KREX and Single SOMAmer assay franchises, to Illumina for $350 million in upfront cash and up to $75 million in performance-based earnout payments, for total potential proceeds of $425 million plus specified royalties. The divestiture, which leaves Standard BioTools retaining its mass cytometry and microfluidics operations, also gives the company 10-year royalty streams on SOMAmer-based NGS library preparation kits and Single SOMAmer sales and a co-exclusive license to Single SOMAmer IP, and has boosted its estimated cash and cash equivalents to about $550 million at closing, positioning the company to pursue inorganic growth and move its streamlined continuing operations toward positive adjusted EBITDA in 2026, while ending its direct economic participation in the prior SomaLogic-Illumina collaboration.
The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, persistent losses, and negative cash flows). Technicals provide partial support with price trending above key moving averages, while valuation remains challenged due to negative earnings and no dividend data.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. (Nasdaq: LAB) is a life sciences tools company that provides standardized next-generation technologies to biomedical researchers, centered on proprietary mass cytometry and microfluidics platforms. Its solutions deliver reproducible insights into health and disease for leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, with a particular focus on translational and clinical research areas such as oncology, immunology and immunotherapy.
Average Trading Volume: 1,715,321
Technical Sentiment Signal: Sell
Current Market Cap: $549.9M
For a thorough assessment of LAB stock, go to TipRanks’ Stock Analysis page.